Commonality between Diabetes and Alzheimer's Disease and a New Strategy for the Therapy
Clinical medicine. Pathology · 2008
DOI: 10.4137/cpath.s667 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical medicine. Pathology, 2008. Verfasst von Li Lin. Beteiligte Einrichtung: Key laboratory of cellular physiology, Shanxi Medical University, China. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 97 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Demenz, Diabetes mellitus
Abstract (Originalsprache)
A surprising common pathological processes is found between Alzheimer’s disease (AD) and type 2 diabetes mellitus (T2DM)[1]. AD and T2DM share some common pathological processes: Amyloid β (Aβ), τ hyperphosphoralation, insulin abnormality. Disturbance in insulin signalling is not only involved in blood glucose level but also in numerous degenerative processes. Glucagon-like peptide 1 (GLP-1) has attracted substantial attention for its advantage in treating T2DM. GLP-1 can reduce Aβ levels in brain. All these encourage us in a medical hypothesis: that is, that GLP-1 is a promising agent in the therapy of AD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Key laboratory of cellular physiology, Shanxi Medical University, China.
Zitieren
APA
Lin, L. (2008). Commonality between Diabetes and Alzheimer's Disease and a New Strategy for the Therapy. Clinical medicine. Pathology. https://doi.org/10.4137/cpath.s667
Vancouver
Lin L. Commonality between Diabetes and Alzheimer's Disease and a New Strategy for the Therapy. Clinical medicine. Pathology. 2008. doi:10.4137/cpath.s667
BibTeX
@article{Lin2008,
author = {Lin, Li},
title = {Commonality between Diabetes and Alzheimer's Disease and a New Strategy for the Therapy},
journal = {Clinical medicine. Pathology},
year = {2008},
doi = {10.4137/cpath.s667}
}
EUVIMED